Leaf Resources Ltd (ASX: LER) is mainly involved in transforming non-food plant biomass into marketable products. On 5 March 2019, the company made an announcement stating that IP Australia has granted Leaf patents which will protect the core intellectual property associated with Leaf’s Glycell™ biorefinery technology.
The Glycell™ is an essential first step of the biorefining process in breaking down biomass into its constituent parts before converting it into marketable products such as bio-based chemicals, bioplastics and other renewable products. The patents which are granted by IP Australia covers methods for producing and hydrolysing lignocellulosic material which is an important part of the technology in the production of cellulosic products such as fermentable sugars from the Glycell™ biorefinery platform.
The certificates of grant are issued for two patents – 2015286230, 2015286229. Patent number 2015286230 is associated with the methods for hydrolysing lignocellulosic material and patent number 2015286229 is associated with the methods for treating lignocellulosic material. Both of these patents will provide the exclusive commercial rights in Australia through to 2035.
The company is currently seeking the grant of corresponding patent applications in other key territories including Malaysia, USA and Europe. The company has already filed additional patent applications in collaboration with Amalgamated Research Inc (ARi) for application of simulated moving bed chromatography (SMB) processes in cellulosic biorefineries.
The US-based SMB engineering company has entered into an assignment and license deed with Leaf, whereby Leaf owns the IP rights and ARi has an option as a vendor of first choice in the commercial development of SMB equipment.
The company has recently released its interim final report for the half-year ended 31 December 2019. In the half-year period, the company reported operating loss of $3.99 million which is higher than the loss of $2.205 million in the previous corresponding period (pcp). The rise in the operating loss was driven by the increased research and development expenditure in relation to the commencement of the integrated demonstration study in Delft.
As per the outlook for 2019, the company is expecting it to be in a position to start construction of the Segamat biorefinery in the first quarter of the calendar year 2020. The company’s progress during the half-year period has resulted in a clear path toward the commercial scale production of industrial sugars using GlycellTM technology.
Now, let’s have a glance at the company’s stock performance and the return it has posted over the past few months. The stock is trading at a price of $0.05, down by 3.448% in the intraday trade, with a market capitalization of ~$17.7 million as on 5 March 2019 (AEST 4:00 PM). The stock has provided a year till date return of 31.82% & also posted returns of -18.31%, 3.57% & 7.41% over the past six months, three & one-months period respectively. It had a 52-week high price of $0.094 and touched 52 weeks low of $0.040, with an average volume of ~148,666.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.